Lunai Bioworks, Inc. LNAI
NASDAQ · United States · Health Technology
$1.30-0.08 (-5.80%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing Parkinson's disease discovery and validation platform. The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent patient cohorts and measurable human cellular bio
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today shared results from a technical case study conducted by its BioSymetrics subsidiary, supporting the development of structure-based screening tools for chemical outputs generated by large language models and other artificial intelligence systems. The study evaluates predicting acetylcholinesterase ("AChE") inhibition directly from molecular structure as a model-agnostic component of the Company's broader chemical-safety and bios
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.